nach oben

07.12.2018 | Review Article

Sacral neuromodulation and sexual function: a systematic review and meta-analysis of the literature

verfasst von: Aethele Khunda, Carol McCormick, Paul Ballard

Erschienen in: International Urogynecology Journal

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Sexual function is being increasingly recognized as an important patient-reported outcome. Sacral neuromodulation (SNM) is a treatment with an expanding list of indications. The effect of sacral neuromodulation on sexual function has been examined in a number of studies with variable results. In this review, we aim to systematically review the literature and pool the data if appropriate.

Methods

The literature search was conducted primarily on the Healthcare Databases Advanced Search (HDAS) platform using the Medline, EMBASE and CINHAL search engines. Of 196 initial citations, 17 articles met our predefined inclusion criteria. Thirteen studies reported enough information to be included in our meta-analysis. RevMan5 software was used for analysis.

Results

Eight of 17 studies reported a positive effect of SNM on sexual function. Pooled analysis of data from 11 studies involving 573 patients before SNM and 438 patients after SNM showed significant improvement in sexual function (SMD = −0.39; 95% CI: −0.58 to −0.19; p = 0.0001). The results remained significant in most subgroup analyses except in patients suffering from fecal incontinence.

Conclusions

SNM in women with pelvic floor disorders, especially bladder dysfunction, seems to have a positive effect on sexual function. This needs to be verified in adequately powered primary research using sexual function as the primary outcome.

WHO. Defining sexual health: report of a technical consultation on sexual health 28–31 January 2002. Sexual health documents, vol chapter 3: working definitions. Geneva: World Health Organization; 2006.

Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. Jama. 1999;281(6):537–44. https://doi.org/10.1001/jama.281.6.537.CrossRefPubMed

Burri A, Spector T. Recent and lifelong sexual dysfunction in a female UK population sample: prevalence and risk factors. J Sex Med. 2011;8(9):2420–30. https://doi.org/10.1111/j.1743-6109.2011.02341.x.CrossRefPubMed

Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208. https://doi.org/10.1080/009262300278597.CrossRefPubMed

Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The female sexual distress scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther. 2002;28(4):317–30.CrossRefPubMed

Komesu YM, Rogers RG. Sexual function in women with pelvic floor and lower urinary tract disorder. Available from: http://www.uptodate.com/contents/sexual-function-in-women-with-pelvic-floor-and-lower-urinary-tract-disorders. Accessed 2nd of August 2018. 2016.

Norton PA, MacDonald LD, Sedgwick PM, Stanton SL. Distress and delay associated with urinary incontinence, frequency, and urgency in women. Bmj. 1988;297(6657):1187–9.CrossRefPubMedPubMedCentral

Imhoff LR, Brown JS, Creasman JM, Subak LL, Van den Eeden SK, Thom DH, et al. Fecal incontinence decreases sexual quality of life, but does not prevent sexual activity in women. Dis Colon Rectum. 2012;55(10):1059–65. https://doi.org/10.1097/DCR.0b013e318265795d.CrossRefPubMedPubMedCentral

Bergeron CD, Goltz HH, Szucs L, Reyes JV, Wilson KL, Ory MG, et al. Exploring sexual behaviors and health communication among older women. Health Care Women Int. 2017. https://doi.org/10.1080/07399332.2017.1329308.

10.

Simons JS, Carey MP. Prevalence of sexual dysfunctions: results from a decade of research. Arch Sex Behav. 2001;30(2):177–219.CrossRefPubMedPubMedCentral

11.

Goldmeier D, Malik F, Phillips R, Green J. Cost implications of sexual dysfunction: the female picture. Int J Impot Res. 2004;16(2):130–4. https://doi.org/10.1038/sj.ijir.3901179.CrossRefPubMed

12.

Fariello JY, Whitmore K. Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction. Int Urogynecol J. 2010;21(12):1553–8. https://doi.org/10.1007/s00192-010-1281-3.CrossRefPubMed

13.

Lombardi G, Finazzi Agro E, Del Popolo G. Sacral neuromodulation and female sexuality. Int Urogynecol J. 2015;26(12):1751–7. https://doi.org/10.1007/s00192-015-2708-7.CrossRefPubMed

14.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.CrossRefPubMedPubMedCentral

15.

Liberman D, Singh R, Siegel S. Neuromodulation for pelvic pain and sexual dysfunction. Curr Bladder Dysfunct Rep. 2016;11:187–93. https://doi.org/10.1007/s1188. CrossRef

16.

Jarrett ME, Nicholls RJ, Kamm MA. Effect of sacral neuromodulation for faecal incontinence on sexual activity. Color Dis Off J Assoc Coloproctology Great Britain Ireland. 2005;7(5):523–5. https://doi.org/10.1111/j.1463-1318.2005.00815.x.CrossRef

17.

Pauls RN, Marinkovic SP, Silva WA, Rooney CM, Kleeman SD, Karram MM. Effects of sacral neuromodulation on female sexual function. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(4):391–5. https://doi.org/10.1007/s00192-006-0168-9.CrossRefPubMed

18.

Zabihi N, Mourtzinos A, Maher MG, Raz S, Rodriguez LV. The effects of bilateral caudal epidural S2-4 neuromodulation on female sexual function. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(5):697–700. https://doi.org/10.1007/s00192-007-0504-8.CrossRefPubMed

19.

Ferhi K, Miaadi N, Tanneau Y, Leroi AM, Sibert L, Grise P. Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study. Progres en Urologie : Journal de l'Association Francaise d'urologie et de la Societe Francaise d'urologie. 2008;18(3):160–6. https://doi.org/10.1016/j.purol.2007.11.003.CrossRef

20.

Lombardi G, Mondaini N, Macchiarella A, Cilotti A, Del Popolo G. Clinical female sexual outcome after sacral neuromodulation implant for lower urinary tract symptom (LUTS). J Sex Med. 2008;5(6):1411–7. https://doi.org/10.1111/j.1743-6109.2008.00812.x.CrossRefPubMed

21.

Ingber MS, Ibrahim IA, Killinger KA, Diokno AC, Peters KM. Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit? Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(9):1055–9. https://doi.org/10.1007/s00192-009-0900-3.CrossRefPubMed

22.

Maeda Y, Lundby L, Buntzen S, Laurberg S. Sacral nerve stimulation for constipation: suboptimal outcome and adverse events. Dis Colon Rectum. 2010;53(7):995–9. https://doi.org/10.1007/DCR.0b013e3181d64207.CrossRefPubMed

23.

Signorello D, Seitz CC, Berner L, Trenti E, Martini T, Galantini A, et al. Impact of sacral neuromodulation on female sexual function and his correlation with clinical outcome and quality of life indexes: a monocentric experience. J Sex Med. 2011;8(4):1147–55. https://doi.org/10.1111/j.1743-6109.2010.02189.x.CrossRefPubMed

24.

Gill BC, Swartz MA, Firoozi F, Rackley RR, Moore CK, Goldman HB, et al. Improved sexual and urinary function in women with sacral nerve stimulation. Neuromodulation J Int Neuromodulation Soc. 2011;14(5):436–43; discussion 443. https://doi.org/10.1111/j.1525-1403.2011.00380.x.CrossRef

25.

Leong RK, Marcelissen TA, Nieman FH, De Bie RA, Van Kerrebroeck PE, De Wachter SG. Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey. J Urol. 2011;185(2):588–92. https://doi.org/10.1016/j.juro.2010.09.090.CrossRefPubMed

26.

Smart C, Jadav AM, Telford K. Sexual health for patients undergoing sacral nerve stimulation (SNS) for faecal incontinence. Color Dis. 2011;13(suppl 6):22.

27.

Caremel R, Nouhaud FX, Leroi AM, Ruffion A, Michot F, Damon H, et al. Results of sacral neuromodulation on the urinary and fecal incontinence and sexuality in 20 women suffering from a double incontinence. Progres en Urologie: Journal de l'Association Francaise d'urologie et de la Societe Francaise d'urologie. 2012;22(7):424–32. https://doi.org/10.1016/j.purol.2012.01.015.CrossRef

28.

van Voskuilen AC, Oerlemans DJ, Gielen N, Lansen-Koch SM, Weil EH, van Lankveld JJ, et al. Sexual response in patients treated with sacral neuromodulation for lower urinary tract symptoms or fecal incontinence. Urol Int. 2012;88(4):423–30. https://doi.org/10.1159/000336911.CrossRefPubMed

29.

Altaf N, Maheswaran T, Reddy A. Can Sacral Neuro-modulation ofr faecal incontinence improve vaginal and sexual symptoms? Paper presented at the SAGES, Baltimore MD, 2013. https://www.sages.org/wp-content/uploads/posters/2013/45943.jpg. Accessed 2nd August 2018. 2011.

30.

Jadav AM, Wadhawan H, Jones GL, Wheldon LW, Radley SC, Brown SR. Does sacral nerve stimulation improve global pelvic function in women? Color Dis Off J Assoc Coloproctology Great Britain Ireland. 2013;15(7):848–57. https://doi.org/10.1111/codi.12181.CrossRef

31.

Yih JM, Killinger KA, Boura JA, Peters KM. Changes in sexual functioning in women after neuromodulation for voiding dysfunction. J Sex Med. 2013;10(10):2477–83. https://doi.org/10.1111/jsm.12085.CrossRefPubMed

32.

Banakhar M, Gazwani Y, Kelini ME, Al-Shaiji T, Hassouna M. Effect of sacral neuromodulation on female sexual function and quality of life: are they correlated? Can Urol Assoc J Journal de l'Association des Urologues du Canada. 2014;8(11-12):E762–7. https://doi.org/10.5489/cuaj.2300.CrossRefPubMed

33.

Burke J, Capozzi P, Jadav AM, Smart C, Nicholson J, Sharma A, et al. Sexual health in patients undergoing sacral nerve stimulation for faecal incontinence. Color Dis. 2014;16(suppl 2):135.

34.

Javidan AN, Mazel K, Latifi S, Maghari MM, Saberi H, Nikfalah A, et al. Outcomes of implementation of sacral nerve stimulation on urination, defecation, and sexual function in patients with spinal cord injury. Int J Color Dis. 2014;29(12):1577–8. https://doi.org/10.1007/s00384-014-1927-6.CrossRef

35.

Gil-Sousa D, Castanheira de Oliveira M, Gomez M, Soares J, Fraga A. Assessment of sexual function in patients submitted to sacral neuromodulation. Paper presented at the ICS, Rio de Janeiro, 23/10/2014. 2014.

36.

Parnell BA, Howard JF Jr, Geller EJ. The effect of sacral neuromodulation on pudendal nerve function and female sexual function. Neurourol Urodyn. 2015;34(5):456–60. https://doi.org/10.1002/nau.22579.CrossRefPubMed

37.

Jones CL, Fischer JR, Hernandez SL. Sacral neuromodulation for the treatment of persistent genital arousal disorder. Obstet Gynecol. 2016;128(2):321–3. https://doi.org/10.1097/AOG.0000000000001452.CrossRefPubMed

38.

Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology. 2016;94:57–63. https://doi.org/10.1016/j.urology.2016.04.024.CrossRefPubMed

39.

Noblett K, Siegel S, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2016;35(2):246–51. https://doi.org/10.1002/nau.22707.CrossRefPubMed

40.

Rydningen M, Dehli T, Wilsgaard T, Rydning A, Kumle M, Lindsetmo RO, et al. Sacral neuromodulation compared with injection of bulking agents for faecal incontinence following obstetric anal sphincter injury—a randomized controlled trial. Col Dis Off J Assoc Coloproctology Great Britain Ireland. 2017;19(5):O134–44. https://doi.org/10.1111/codi.13632.CrossRef

41.

Oliveira PS, Oliveira TR, Silva RP, Martinho D, Reis JP, Lopes TM. The impact of neuromodulation on sexual function. Int Urogynecol J. 2017;28(1):S257.

42.

Jha S, Ammenbal M, Metwally M. Impact of incontinence surgery on sexual function: a systematic review and meta-analysis. J Sex Med. 2012;9(1):34–43. https://doi.org/10.1111/j.1743-6109.2011.02366.x.CrossRefPubMed

43.

Chu CM, Arya LA, Andy UU. Impact of urinary incontinence on female sexual health in women during midlife. Women's Midlife Health 2015;1(6). https://doi.org/10.1186/s40695-015-0007-6.

44.

Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the multicenter assessment of transdermal therapy in overactive bladder with oxybutynin trial. Am J Obstet Gynecol. 2006;195(6):1730–5. https://doi.org/10.1016/j.ajog.2006.08.013.CrossRefPubMed

45.

Wenzler DL, Burks FN, Cooney M, Peters KM. Proof of concept trial on changes in current perception threshold after sacral neuromodulation. Neuromodulation J Int Neuromodulation Soc. 2015;18(3):228–31; discussion 232. https://doi.org/10.1111/ner.12213.CrossRef

46.

Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol. 2005;174(6):2268–72. https://doi.org/10.1097/01.ju.0000181806.59363.d1.CrossRefPubMed

Titel: Sacral neuromodulation and sexual function: a systematic review and meta-analysis of the literature
verfasst von: Aethele Khunda
Carol McCormick
Paul Ballard
Publikationsdatum: 07.12.2018
Verlag: Springer International Publishing
Erschienen in: International Urogynecology Journal
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-018-3841-x

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Nach privat bezahlter In-vitro-Fertilisation muss die gesetzliche Krankenkasse ein Arzneimittel zum Erhalt der Schwangerschaft bezahlen, so ein Urteil des Sozialgerichts in München.

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

10.01.2025
Mammakarzinom
Nachrichten

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

10.01.2025
Antiemetische Therapie
Nachrichten

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen